collaborators discovery
We had a great experience working with o2h discovery on our Fragment libraries project. Their expertise in conducting fragment-based screening, targeting dual series threonine kinase on surface plasmon resonance, was impressive. The efficiency, productivity, and detailed communication from the o2h biologist team were outstanding. We look forward to further positive outcomes in our future collaborations.
Persephoni Biopartners is excited to announce the award of the o2h Kickstarter Program to InnoVira Therapeutics, a Persephoni portfolio company focused on developing small molecule medicines. The Kickstarter award will accelerate our early discovery and drive generation of candidates for our lead program. The high quality medicinal chemistry services provided by o2h Discovery are uniquely designed to help startups such as InnoVira reach value milestones more rapidly, which aligns closely with Persephoni’s core mission of de-risking early stage companies to bring novel therapies to patients faster.
Hilary Schultz CEO, Persephoni Biopartners